Strongbridge Biopharma plc SBBP NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

50/100

1/6 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Strongbridge Biopharma plc (SBBP) .

本页证实的标准:

VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。

SharesGrow 综合评分： 49/100 其中 1/7 项标准通过。

SharesGrow 7-Criteria Score

50/100

SG Score

View full scorecard →

—

价值

N/A

No coverage

✓

未來

90/100

Analyst consensus

→ Forecast

✗

过去

25/100

→ Income

健康

67/100

Debt-to-Equity & liquidity

→ Health

护城河

50/100

→ Income

成长

58/100

→ Income

✗

收入

10/100

→ Income

估值概览 — SBBP

估值倍数

P/E (TTM)0.0

前瞻 P/EN/A

PEG 比率N/A

前瞻 PEGN/A

P/B 比率0.00

P/S 比率3.65

EV/EBITDA0.0

每股数据

EPS (TTM)$-0.80

每股账面价值$0.00

每股营收$0.55

每股自由现金流$0.00

收益率与内在价值

盈利收益率N/A

股息收益率0.00%

EPS：实际 vs 预期

P/E Ratio & Earnings Yield

每股收益 (EPS) 历史

Year	EPS（稀释）	营收	净利润	净利润率
2013	$-0.88	$0.00	$-5.3M	-
2014	$-0.96	$0.00	$-9.67M	-
2015	$-2.62	$0.00	$-43.58M	-
2016	$-2.24	$0.00	$-48.6M	-
2017	$-3.11	$7.05M	$-113.48M	-1610.6%
2018	$0.64	$18.03M	$31.85M	176.7%
2019	$-0.89	$21.71M	$-49.45M	-227.8%
2020	$-0.80	$30.73M	$-45.08M	-146.7%